Abeona Therapeutics (ABEO) Non-Current Debt (2018 - 2026)

Abeona Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 57.32% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 57.32% YoY), while the FY2025 annual figure was $7.8 million, down 40.07% from the prior year.
• Non-Current Debt was $4.8 million for Q1 2026 at Abeona Therapeutics, down from $7.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $18.1 million in Q1 2024 to a low of $3.9 million in Q1 2022.
• Historically, Non-Current Debt has averaged $9.7 million across 4 years, with a median of $10.9 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Non-Current Debt soared 224.15% in 2022, then slumped 57.32% in 2026.
• A 4-year view of Non-Current Debt shows it stood at $4.2 million in 2022, then jumped by 213.16% to $13.0 million in 2024, then sank by 40.07% to $7.8 million in 2025, then sank by 39.15% to $4.8 million in 2026.
• The last three Non-Current Debt figures came in at $4.8 million (Q1 2026), $7.8 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.